This research is Trending!
August 25, 2023New England Journal of Medicine1,134 citationsOpen Access
View Full PaperSemaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Key Result
Semaglutide (2.4 mg) significantly improved symptoms, physical limitations, exercise function, and caused greater weight loss compared to placebo in heart failure patients with preserved ejection frac
Key Points
- To determine the effects of semaglutide on symptoms, exercise function, and weight in heart failure patients with preserved ejection fraction and obesity.
- Double-blind clinical trial comparing semaglutide to placebo.
- Patients diagnosed with heart failure and obesity were enrolled.
- Semaglutide dosing was set at 2.4 mg.
- Semaglutide led to larger reductions in symptoms and physical limitations compared to placebo.
- Significant improvements in exercise function were observed in the semaglutide group.
- Patients receiving semaglutide experienced greater weight loss than those on placebo.
Structured PICO
Does semaglutide (2.4 mg) improve symptoms, physical limitations, exercise function, and weight loss in patients with heart failure with preserved ejection fraction and obesity?
P
Population
Patients with heart failure with preserved ejection fraction and obesity
I
Intervention
Semaglutide (2.4 mg)
C
Comparator
Placebo
O
Outcome
Reductions in symptoms and physical limitations, improvements in exercise function, and weight losspatient reported
In patients with HFpEF and obesity, semaglutide 2.4 mg significantly improves heart failure symptoms, physical limitations, and exercise function while promoting weight loss.
Main Result
Absolute Event Rate: 0% vs 0%
Abstract
In patients with heart failure with preserved ejection fraction and obesity, treatment with semaglutide (2.4 mg) led to larger reductions in symptoms and physical limitations, greater improvements in exercise function, and greater weight loss than placebo. (Funded by Novo Nordisk; STEP-HFpEF ClinicalTrials.gov number, NCT04788511.).
Expert Takes3 quotes
1/3
“Just for a matter of perspective, [if] people who have a KCCQ-CSS improvement of 15 points or greater, it's a truly transformational change in their symptoms and physical limitations.”
Mikhail Kosiborod, Vice President for Research, Saint Luke's Health SystemSaint Luke's Health Systemauto_pipelineView source
Trending Research#3 this week
This trial is part of a wave of studies on GLP-1 receptor agonists showing cardiovascular benefits beyond glycemic control, prompting widespread discussion about their role in heart failure management.
Social attention
90
Preprint velocity
0
News coverage
95
Conference
0
Expert commentary
0